Development Predicament and Countermeasures of Anti-tumor Bio-similar Industry in China

Advanced Emergency Medicine

View Publication Info
 
 
Field Value
 
Title Development Predicament and Countermeasures of Anti-tumor Bio-similar Industry in China
 
Creator Xie, Yingjie
 
Subject Biosimilar; Anti-tumor; Industry; Development; Countermeasure
 
Description Biosimilar has the advantages of precise efficacy, high safety and stable quality, and occupy an important position in the field of anti-tumor therapy. In order to reduce the expenditure of drugs, the research and development of biosimilar drugs has attracted much attention. Compared with European and American countries in the development of the anti-tumor biosimilar industry, there are still some shortcomings and parts that need improvement in China. According to the current development status of China, analyzed the reasons for the development dilemma of my country’s anti-tumor biosimilar industry, and put forward suggestions for the development of this industry.
 
Publisher Universe Scientific Publishing Pte. Ltd.
 
Contributor
 
Date 2021-02-02
 
Type info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion

 
Format application/pdf
 
Identifier http://aem.usp-pl.com/index.php/aem/article/view/180
10.18686/aem.v9i4.180
 
Source Advanced Emergency Medicine; Vol 9, No 4 (Published); 85-88
2315-456X
 
Language eng
 
Relation http://aem.usp-pl.com/index.php/aem/article/view/180/173
 
Rights Copyright (c) 2021 Yingjie Xie
http://creativecommons.org/licenses/by-nc/4.0
 

Contact Us

The PKP Index is an initiative of the Public Knowledge Project.

For PKP Publishing Services please use the PKP|PS contact form.

For support with PKP software we encourage users to consult our wiki for documentation and search our support forums.

For any other correspondence feel free to contact us using the PKP contact form.

Find Us

Twitter

Copyright © 2015-2018 Simon Fraser University Library